Last updated: October 25, 2022
Sponsor: Rigshospitalet, Denmark
Overall Status: Active - Not Recruiting
Phase
4
Condition
Glaucoma
Treatment
N/AClinical Study ID
NCT04054830
EudraCT nr.: 2018-001855-10
Ages > 50 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with primary open-angle glaucoma (POAG), pseudoexfoliation syndrome (PEX),pigment dispersion syndrome (PDS) or ocular hypertension
- >50 years
- Women must be postmenopausal. Women are asked if they have menstruated within thepreceding 12 months
- Scheduled to undergo trabeculectomy surgery at the Department of Ophthalmology atRigshospitalet-Glostrup, Denmark
- Informed consent to participation and ability to comply with study procedures
Exclusion
Exclusion Criteria:
- Known allergy to any of the contents of the pharmaceuticals (active and in-activeingredients) used in the study
- Prior intraocular surgery, except from cataract surgery. If cataract surgery has beenperformed, it should at least be 6 months prior to surgery
- Medical history of anterior segment dysgenesis, inflammatory/uveitic glaucoma, angleclosure glaucoma, neovascular glaucoma and traumatic glaucoma
- Steroid responders
- Pregnancy
- Fertile women, i.e. women who are not menopausal and women who breastfeed
- Patients in systemic treatment with steroid or NSAID
Study Design
Total Participants: 70
Study Start date:
August 01, 2019
Estimated Completion Date:
July 31, 2023
Connect with a study center
Department of Ophthalmology
Glostrup, Capital Region, 2600
DenmarkSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.